LT2968477T - Faktoriaus viii polipeptido kompozicijos - Google Patents

Faktoriaus viii polipeptido kompozicijos

Info

Publication number
LT2968477T
LT2968477T LTEP14725816.4T LT14725816T LT2968477T LT 2968477 T LT2968477 T LT 2968477T LT 14725816 T LT14725816 T LT 14725816T LT 2968477 T LT2968477 T LT 2968477T
Authority
LT
Lithuania
Prior art keywords
compositions
factor viii
viii polypeptide
polypeptide
factor
Prior art date
Application number
LTEP14725816.4T
Other languages
English (en)
Lithuanian (lt)
Inventor
Kevin Maloney
Ahmad ABDUL-FATTAH
Daniel GAGE
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2968477(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of LT2968477T publication Critical patent/LT2968477T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LTEP14725816.4T 2013-03-15 2014-03-14 Faktoriaus viii polipeptido kompozicijos LT2968477T (lt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30
PCT/US2014/029354 WO2014144795A1 (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Publications (1)

Publication Number Publication Date
LT2968477T true LT2968477T (lt) 2020-03-10

Family

ID=50771579

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14725816.4T LT2968477T (lt) 2013-03-15 2014-03-14 Faktoriaus viii polipeptido kompozicijos

Country Status (20)

Country Link
US (3) US9623088B2 (cg-RX-API-DMAC7.html)
EP (3) EP4122487A1 (cg-RX-API-DMAC7.html)
JP (5) JP6330026B2 (cg-RX-API-DMAC7.html)
AU (4) AU2014228506A1 (cg-RX-API-DMAC7.html)
CA (1) CA2899737A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015002720A1 (cg-RX-API-DMAC7.html)
DK (1) DK2968477T3 (cg-RX-API-DMAC7.html)
EA (2) EA030357B1 (cg-RX-API-DMAC7.html)
ES (2) ES2926798T3 (cg-RX-API-DMAC7.html)
HU (1) HUE047933T2 (cg-RX-API-DMAC7.html)
LT (1) LT2968477T (cg-RX-API-DMAC7.html)
PH (2) PH12015501801B1 (cg-RX-API-DMAC7.html)
PL (2) PL2968477T3 (cg-RX-API-DMAC7.html)
PT (2) PT3666283T (cg-RX-API-DMAC7.html)
RS (1) RS60003B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201505924TA (cg-RX-API-DMAC7.html)
SI (1) SI2968477T1 (cg-RX-API-DMAC7.html)
TW (2) TWI629993B (cg-RX-API-DMAC7.html)
UY (1) UY35462A (cg-RX-API-DMAC7.html)
WO (1) WO2014144795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101770849B1 (ko) * 2009-12-06 2017-09-05 바이오버라티브 테라퓨틱스 인크. 인자 ＦⅧ-Ｆｃ의 키메라 및 하이브리드 폴리펩티드, 및 그의 사용방법
AU2014228506A1 (en) 2013-03-15 2015-08-13 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
KR20250040746A (ko) 2017-08-09 2025-03-24 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
CN111655230A (zh) 2017-11-07 2020-09-11 拉尼医疗有限公司 使用可吞服药物递送装置递送到肠道组织中的凝血因子制剂
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
CN120865384A (zh) * 2018-10-23 2025-10-31 费城儿童医院 用于调节因子viii功能的组合物和方法
US20220088085A1 (en) * 2019-02-28 2022-03-24 Public University Corporation Yokohama City University Composition for treating blood coagulation and/or complement disorders
KR20220009389A (ko) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. 엑소좀 및 aav 의 조성물
TW202115127A (zh) * 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 治療血友病及低骨質密度之方法及組成物
KR20230159284A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
EP0627924B1 (en) * 1992-10-02 2000-12-27 Genetics Institute, Inc. Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
CN100553678C (zh) * 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005058283A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
KR101542752B1 (ko) * 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
US20120093840A1 (en) 2009-04-06 2012-04-19 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
KR101770849B1 (ko) * 2009-12-06 2017-09-05 바이오버라티브 테라퓨틱스 인크. 인자 ＦⅧ-Ｆｃ의 키메라 및 하이브리드 폴리펩티드, 및 그의 사용방법
HRP20190535T1 (hr) * 2011-07-08 2019-05-17 Bioverativ Therapeutics Inc. Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe
EP2768853A1 (en) 2011-10-18 2014-08-27 CSL Limited Method for improving the stability of purified factor viii after reconstitution
CN104519912A (zh) * 2012-08-13 2015-04-15 诺和诺德A/S（股份有限公司） 液体因子viii制剂
EP3943102A1 (en) * 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
AU2014228506A1 (en) 2013-03-15 2015-08-13 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations

Also Published As

Publication number Publication date
ES2926798T3 (es) 2022-10-28
AU2014228506A1 (en) 2015-08-13
AU2021277601B2 (en) 2025-03-06
SG10201805207QA (en) 2018-07-30
US9623088B2 (en) 2017-04-18
EA030357B1 (ru) 2018-07-31
EP2968477B1 (en) 2019-12-04
US12403183B2 (en) 2025-09-02
EA201890671A1 (ru) 2019-01-31
TWI690325B (zh) 2020-04-11
PH12019502452A1 (en) 2021-02-08
PL3666283T3 (pl) 2022-10-03
CL2015002720A1 (es) 2016-11-04
JP6330026B2 (ja) 2018-05-23
JP6934994B2 (ja) 2021-09-15
AU2021277601A1 (en) 2021-12-23
JP7240457B2 (ja) 2023-03-15
EP2968477A1 (en) 2016-01-20
TWI629993B (zh) 2018-07-21
CA2899737A1 (en) 2014-09-18
SI2968477T1 (sl) 2020-04-30
US20170281734A1 (en) 2017-10-05
US20210069300A1 (en) 2021-03-11
ES2776195T3 (es) 2020-07-29
AU2025204069A1 (en) 2025-06-26
DK2968477T3 (da) 2020-03-09
EP3666283A1 (en) 2020-06-17
EA201591439A1 (ru) 2016-03-31
EP4122487A1 (en) 2023-01-25
UY35462A (es) 2014-10-31
PL2968477T3 (pl) 2020-06-15
JP2018123161A (ja) 2018-08-09
TW201842930A (zh) 2018-12-16
PH12015501801B1 (en) 2019-11-20
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
PT2968477T (pt) 2020-03-11
JP2020186268A (ja) 2020-11-19
US20140308280A1 (en) 2014-10-16
WO2014144795A1 (en) 2014-09-18
JP2021181491A (ja) 2021-11-25
HUE047933T2 (hu) 2020-05-28
PT3666283T (pt) 2022-09-13
EP3666283B1 (en) 2022-06-08
JP2023060146A (ja) 2023-04-27
TW201501722A (zh) 2015-01-16
RS60003B1 (sr) 2020-04-30
PH12015501801A1 (en) 2015-11-09
US10786554B2 (en) 2020-09-29
HK1220617A1 (en) 2017-05-12
SG11201505924TA (en) 2015-09-29
JP7700164B2 (ja) 2025-06-30
JP2016516722A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
LT2968477T (lt) Faktoriaus viii polipeptido kompozicijos
CL2015003031A1 (es) Compuesto peptídico
CL2016000157A1 (es) Bioconjugados de polipétidos de apelina sintética
EP3084956A4 (en) VOLTAGE STRETCHING
PT3030262T (pt) Composição farmacêutica de associação
EP2889350A4 (en) ADHESIVE COMPOSITION
DK2951203T3 (da) Heterodimere proteiner
DK2970954T3 (da) Modifikation af polypeptider
DK3079666T3 (da) Farmaceutiske sammensætninger omfattende dimethylfumarat
LT2986722T (lt) Rekombinantiniai fenilalanino amonio liazės polipeptidai
DK3027750T3 (da) Biokatalytisk sammensætning
DE112014001299T8 (de) Kosmetische Zusammensetzung
EP2958994A4 (en) Vaccine composition
PT2953948T (pt) Antagonistas de integrina fluorada
LT3060577T (lt) Rekombinantinio lubricino gamyba
EP2945942A4 (en) Voriconazole IMMUNOASSAY
EP2947023A4 (en) REMOVABLE SELF-ARRANGING STRUCTURE
LT3030259T (lt) Peptidai
DK3071053T3 (da) Præbiotisk sammensætning
LT3013855T (lt) Mutavusio viii faktoriaus kompozicijos ir metodai
DK2978414T3 (da) Sammensætning omfattende hydrocortison
FR3015291B1 (fr) Composition antiprurigineuse
HRP20182110T1 (hr) Sastav spojeva tiakumicina
DK2983690T3 (da) Neuropeptid Y-afledte peptider
ITMI20130536A1 (it) Analoghi sintetici dello xantumolo